InsiderSource
SYRE

Spyre Therapeutics, Inc.

SEC CIK 1636282
$83.58 +153.7% · 90 days
90-day buys
$0
0 open-market
90-day sells
$17.24M
30 open-market
Net insider flow
−$17.24M
Net selling
Filings shown
47
Most recent
Advertisement

At a glance

Over the last 90 days, insiders at SYRE have sold a net $17.24M of stock (0 open-market buys vs 30 sells).

Largest recent trade: Henderson Michael Thomas sold $2.47M of SYRE, trimming their stake 20%.

Most active filer: Turtle Cameron, with 18 transactions among the recent filings shown.

Insider transaction history

Form 4 filings for SYRE, newest first
View on SEC EDGAR ↗
SYRE
Spyre Therapeutics, Inc.
Sell Sloan Sheldon · Chief Medical Officer · Open-market sale · filed 1w ago ΔOwn −100%

Sloan Sheldon sold $625K of SYRE, trimming their stake 100%.

−$625K
8,333 sh @ $75
SYRE
Spyre Therapeutics, Inc.
Sell Turtle Cameron · Director, Chief Executive Officer · Open-market sale · filed 1w ago ΔOwn −0.6%

Turtle Cameron sold $246.9K of SYRE, trimming their stake 1%.

−$246.9K
3,557 sh @ $69
SYRE
Spyre Therapeutics, Inc.
Sell Turtle Cameron · Director, Chief Executive Officer · Open-market sale · filed 1w ago ΔOwn −1.3%

Turtle Cameron sold $574.5K of SYRE, trimming their stake 1%.

−$574.5K
8,149 sh @ $71
SYRE
Spyre Therapeutics, Inc.
Sell Turtle Cameron · Director, Chief Executive Officer · Open-market sale · filed 1w ago ΔOwn −0.5%

Turtle Cameron sold $235.1K of SYRE, trimming their stake 1%.

−$235.1K
3,294 sh @ $71
Advertisement
SYRE
Spyre Therapeutics, Inc.
Sell Burrows Scott L · Chief Financial Officer · Open-market sale · filed 1w ago ΔOwn −1.7%

Burrows Scott L sold $125.6K of SYRE, trimming their stake 2%.

−$125.6K
1,801 sh @ $70
SYRE
Spyre Therapeutics, Inc.
Sell Burrows Scott L · Chief Financial Officer · Open-market sale · filed 1w ago ΔOwn −2.5%

Burrows Scott L sold $183.9K of SYRE, trimming their stake 3%.

−$183.9K
2,599 sh @ $71
SYRE
Spyre Therapeutics, Inc.
Sell Burrows Scott L · Chief Financial Officer · Open-market sale · filed 1w ago ΔOwn −3.1%

Burrows Scott L sold $223.4K of SYRE, trimming their stake 3%.

−$223.4K
3,100 sh @ $72
SYRE
Spyre Therapeutics, Inc.
Sell Burrows Scott L · Chief Financial Officer · Open-market sale · filed May 1, 2026 ΔOwn −11%

Burrows Scott L sold $892.1K of SYRE, trimming their stake 11%.

−$892.1K
12,500 sh @ $71
SYRE
Spyre Therapeutics, Inc.
Sell Sloan Sheldon · Chief Medical Officer · Open-market sale · filed May 1, 2026 ΔOwn −27%

Sloan Sheldon sold $1.48M of SYRE, trimming their stake 27%.

−$1.48M
21,306 sh @ $70
SYRE
Spyre Therapeutics, Inc.
Sell Sloan Sheldon · Chief Medical Officer · Open-market sale · filed May 1, 2026 ΔOwn −34%

Sloan Sheldon sold $1.39M of SYRE, trimming their stake 34%.

−$1.39M
19,656 sh @ $71
SYRE
Spyre Therapeutics, Inc.
Sell Sloan Sheldon · Chief Medical Officer · Open-market sale · filed May 1, 2026 ΔOwn −23%

Sloan Sheldon sold $628.1K of SYRE, trimming their stake 23%.

−$628.1K
8,777 sh @ $72
SYRE
Spyre Therapeutics, Inc.
Sell Sloan Sheldon · Chief Medical Officer · Open-market sale · filed May 1, 2026 ΔOwn −45%

Sloan Sheldon sold $932K of SYRE, trimming their stake 45%.

−$932K
12,777 sh @ $73
SYRE
Spyre Therapeutics, Inc.
Sell Sloan Sheldon · Chief Medical Officer · Open-market sale · filed May 1, 2026 ΔOwn −65%

Sloan Sheldon sold $763.8K of SYRE, trimming their stake 65%.

−$763.8K
10,358 sh @ $74
SYRE
Spyre Therapeutics, Inc.
Sell Sloan Sheldon · Chief Medical Officer · Open-market sale · filed May 1, 2026 ΔOwn −93%

Sloan Sheldon sold $377.4K of SYRE, trimming their stake 93%.

−$377.4K
5,059 sh @ $75
SYRE
Spyre Therapeutics, Inc.
Sell Sloan Sheldon · Chief Medical Officer · Open-market sale · filed May 1, 2026 ΔOwn −100%

Sloan Sheldon sold $30.1K of SYRE, trimming their stake 100%.

−$30.1K
400 sh @ $75
SYRE
Spyre Therapeutics, Inc.
Sell Turtle Cameron · Director, Chief Executive Officer · Open-market sale · filed May 1, 2026 ΔOwn −0.8%

Turtle Cameron sold $368.6K of SYRE, trimming their stake 1%.

−$368.6K
5,300 sh @ $70
SYRE
Spyre Therapeutics, Inc.
Sell Turtle Cameron · Director, Chief Executive Officer · Open-market sale · filed May 1, 2026 ΔOwn −0.6%

Turtle Cameron sold $254.8K of SYRE, trimming their stake 1%.

−$254.8K
3,600 sh @ $71
SYRE
Spyre Therapeutics, Inc.
Sell Turtle Cameron · Director, Chief Executive Officer · Open-market sale · filed May 1, 2026 ΔOwn −0.2%

Turtle Cameron sold $71.8K of SYRE.

−$71.8K
1,000 sh @ $72
SYRE
Spyre Therapeutics, Inc.
Sell Turtle Cameron · Director, Chief Executive Officer · Open-market sale · filed May 1, 2026 ΔOwn −0.5%

Turtle Cameron sold $226.7K of SYRE, trimming their stake 1%.

−$226.7K
3,100 sh @ $73
SYRE
Spyre Therapeutics, Inc.
Sell Turtle Cameron · Director, Chief Executive Officer · Open-market sale · filed May 1, 2026 ΔOwn −0.3%

Turtle Cameron sold $126.2K of SYRE.

−$126.2K
1,700 sh @ $74
SYRE
Spyre Therapeutics, Inc.
Sell Turtle Cameron · Director, Chief Executive Officer · Open-market sale · filed Apr 3, 2026 ΔOwn −1.9%

Turtle Cameron sold $607.3K of SYRE, trimming their stake 2%.

−$607.3K
12,344 sh @ $49
Advertisement

About SYRE insider activity

This page tracks every recent Form 4 filed for Spyre Therapeutics, Inc. with the U.S. Securities and Exchange Commission. Form 4 is the disclosure that company insiders — officers, directors, and holders of more than 10% of the stock — must file within two business days of buying or selling shares.

The summary above nets open-market purchases against open-market sales over the trailing 90 days. Open-market trades (codes P and S) tend to carry the most signal because they reflect a deliberate choice to put money in or take it out, as opposed to routine grants, option exercises, or tax-withholding events. Use the badges on each row to tell them apart, and always confirm details against the original filing before drawing conclusions.

Frequently asked questions

How often is SYRE insider data updated?

Continuously. We read from SEC EDGAR, so new Form 4 filings for Spyre Therapeutics, Inc. usually appear here within minutes of being accepted by the SEC.

What does "net insider flow" mean?

It is the total dollar value of open-market insider purchases minus open-market sales over the last 90 days. A positive number (green) means insiders bought more than they sold; a negative number (red) means the reverse.

Why do some rows show grants or option exercises instead of buys?

Insiders receive stock through compensation as well as buying it outright. Form 4 captures all of these. We label each transaction by its SEC code so you can focus on open-market activity if you prefer.

Is this investment advice?

No. InsiderSource presents public filing data for informational purposes only. Insider activity is one of many factors to consider and is never a recommendation to buy or sell.